Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Update

Posted by Alanna Baker on Apr 27th, 2024

Aptevo Therapeutics Inc. (NASDAQ:APVO – Get Free Report) was the target of a significant increase in short interest in April. As of April 15th, there was short interest totalling 145,600 shares, an increase of 324.5% from the March 31st total of 34,300 shares. Based on an average daily volume of 264,000 shares, the short-interest ratio is presently 0.6 days. Currently, 9.1% of the company’s stock are short sold.

Analysts Set New Price Targets

Separately, StockNews.com assumed coverage on shares of Aptevo Therapeutics in a research note on Thursday, April 18th. They set a “sell” rating for the company.

Get Our Latest Stock Analysis on Aptevo Therapeutics

Hedge Funds Weigh In On Aptevo Therapeutics

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Armistice Capital LLC bought a new stake in Aptevo Therapeutics Inc. (NASDAQ:APVO – Free Report) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor bought 1,235,000 shares of the biotechnology company’s stock, valued at approximately $408,000. Armistice Capital LLC owned 10.72% of Aptevo Therapeutics as of its most recent filing with the SEC. 8.06% of the stock is owned by institutional investors and hedge funds.

Aptevo Therapeutics Stock Up 3.8 %

APVO stock traded up $0.03 during mid-day trading on Friday, reaching $0.71. The company had a trading volume of 172,519 shares, compared to its average volume of 569,581. Aptevo Therapeutics has a 52 week low of $0.67 and a 52 week high of $87.56. The stock has a 50 day simple moving average of $4.06 and a two-hundred day simple moving average of $7.28.

Aptevo Therapeutics Company Profile

(Get Free Report)

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.